Atgam market seen growing on transplant demand and aging population

The Atgam market is expected to expand through 2035 as organ transplant volumes rise and older patients need more immune-suppressing care. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - Atgam is used in transplant medicine and aplastic anemia, so market growth tracks broader demand for immune-suppressing treatments. - Rising transplant volumes and an aging population are increasing the number of patients who may need therapies like Atgam. - The market’s long-term outlook matters for hospitals, specialty care providers and drug makers focused on hematology and transplantation.

What happened: - The Business Research Company released its Atgam Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Atgam market is expected to see significant long-term growth. - North America was the largest regional market in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - A free sample of the report is available. - The full market report is also available.

The details: - Atgam is a prescription drug made from antithymocyte globulin (equine) sourced from horse serum. - The drug suppresses the immune system by inhibiting T lymphocytes. - Atgam is used to treat aplastic anemia and to help prevent organ transplant rejection. - The report says historic growth was driven by proven clinical effectiveness, use in aplastic anemia, transplant adoption, limited alternatives and hospital-based protocols. - Future growth is tied to more transplant procedures, demand for targeted immunosuppressive therapies, expansion of hematology specialty care, stronger supportive care systems and continued inclusion in clinical guidelines. - The report lists sustained use in aplastic anemia, a larger role in transplant rejection management, growth in immunosuppressive biologics, better outcomes in hematologic disorders and higher use in specialized transplant centers as key trends. - Organ transplants in the US reached 48,149 in 2024, according to the Organ Procurement and Transplantation Network, up 3.3% from 2023. - Of those US transplants, 41,119 came from deceased donors and 7,030 from living donors. - The World Health Organization projected in October 2024 that by 2030, one in six people globally will be 60 or older. - The WHO also projected the 60-plus population will reach 1.4 billion by 2030 and 2.1 billion by 2050. - The population aged 80 and above is forecast to triple by 2050 to about 426 million.

Between the lines: - The market thesis is less about a new drug launch and more about durable clinical need in transplant and hematology settings. - The report’s regional split suggests mature demand in North America and faster opportunity creation in Asia-Pacific as healthcare access and transplant activity expand. - The growth case depends heavily on medical demographics, not consumer demand, which can make the category more stable but also more dependent on procedural volumes and guideline support.

What's next: - The report expects continued market expansion through 2035 as transplant activity increases and aging demographics widen the patient pool. - Specialty centers and transplant programs are likely to remain the main users of Atgam. - The report’s added features include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics, and updated graphics and tables.